According to the World Health Organization it was reported that, globally there were 1.9 million people suffering from various types of cancer. The majority of these tumors required chemotherapy and/or radiation therapy, which helps 65% of cancer patients survive for at least 5 years following their initial diagnosis. Long-term cancer treatments have resulted in an unanticipated array of side effects, most notably cutaneous toxicities. With greater use of targeted therapies in addition to conventional chemotherapeutic drugs, they are becoming more common. A unusual reaction to cytotoxic medicines known as chemotherapy-induced acral erythema (CIAE) features painful, well defined erythematous plaques. Acral erythema, sometimes referred to as palmoplantar erythrodysesthesia or hand-foot syndrome, is a fairly typical cutaneous reaction brought on by a number of chemotherapy drugs. During cancer treatment, it manifests as excruciating erythema and paresthesia that affects the palms and soles. It appears to be dose-dependent, and the peak plasma concentration and cumulative dose of the chemotherapeutic agent both affect how it manifests. In the past, 45–56% of patients receiving capecitabine have been noted to experience hand–foot syndrome (HFS) as a side effect. Skin cells of the palms have been demonstrated to divide more rapidly than those on the back, thus they would be more vulnerable to a chemotherapeutic medication. The palms are where the enzyme that changes the prodrug capecitabine into the active drug 5-fluorouracil is most active. The blood circulation, temperature, and pressure impacts of the skin on the palms and soles, among other distinctive characteristics, may also be important. The fact that the palms are more frequently involved than the soles in daily tasks could be related to them. Thus, numerous factors are propelling the growth of global chemotherapy-induced acral erythema market.
Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1443
Global Chemotherapy-Induced Acral Erythema Market Segmental Analysis:
The National Cancer Institute created a grading system to categorise HFS according to the severity of the condition. Healthcare provider’s decision for how to manage or treat HFS will depend on how severe it is. With Grade 1 hand-foot syndrome, for example, there is no pain but there is swelling in the palms and soles as well as colour changes (darkening or reddening). Blisters, bleeding, and peeling skin may accompany Grade 1 symptoms of Grade 2 hand-foot syndrome. Whereas Grade 3 hand-foot syndrome may include considerable pain that makes it difficult to perform basic tasks in addition to Grade 2 symptoms. The grading system for HFS reflects that increasing duration of exposure to the chemotherapeutic agent or TKI increases the severity of the syndrome. Evidence-based approaches for the prevention and treatment of HFS support grading these symptoms to help provide the most effective and appropriate intervention.
Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1443
Until recently, the only known remedy for the hand-foot syndrome involved discontinuing chemotherapy, waiting until the reaction subsided, and then beginning treatments at a lesser dose and/or frequency. It is essential to tell patients about this condition before they start chemotherapy so they can report it right away, especially if they are receiving chemotherapy drugs that are given orally at home. Once the reaction has started, analgesics, cold compresses, and elevation or cushioning of the afflicted areas may offer some relief. Many different treatments have been tried, usually on small numbers of individuals, with varied degrees of efficacy, including topical and oral corticosteroids, topical and oral pyridoxine (vitamin B6), topical DMSO, and topical vitamin E. Nonetheless, it has been demonstrated that symptom management and evidence-based suggestions are beneficial in the treatment of patients with HFS and HFSR. Conventional drugs haven’t shown to be 100% successful. The major objective of care is to avoid modifiable risk factors that can increase symptoms, to prevent or treat symptoms quickly and efficiently to minimize associated physical and psychological pain, and to keep uninterrupted antineoplastic therapy going. Leading players in the global chemotherapy-induced acral erythema market are looking forward to introduce advanced treatments for hand and foot syndrome for faster recovery. Moreover, companies are developing a self-administered quality of life questionnaire, a straightforward home-based self-monitoring technique for reliable early diagnosis of hand-foot syndrome.
Asia Pacific is anticipated to be the fastest growing region in the global chemotherapy-induced acral erythema market during the forecast years. In the last few years, there have rising cases on people suffering from cancer and the long term side effects of the chemotherapy have been rising which has led to the rise of chemotherapy-induced acral erythema amongst a huge population. Thus, the above factors are boosting the growth of the chemotherapy-induced acral erythema market in Asia.
Request discount on this premium report: https://www.absolutemarketsinsights.com/ask_for_discount.php?id=1443
Key Players: Global Chemotherapy-Induced Acral Erythema Market
- Bausch Health Companies Inc
- Genentech, Inc.
- MANUS AKTTEVA BIOPHARMA LLP
- Samex Overseas
- Sun Pharmaceutical Industries, Inc.
- Other Industry Participants
Purchase the latest in-depth Global Chemotherapy-Induced Acral Erythema Market Report @ https://www.absolutemarketsinsights.com/checkout?id=1443
Global Chemotherapy-Induced Acral Erythema Market:
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Topical pain relievers
- Hand Creams
- Vitamin E
- Non-steroidal anti-inflammatory drugs
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Drug Stores
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
View our exclusive press releases on Industry Global News24
Global Digital Dermatoscope Market (2022 – 2030)
Global Breast Reconstruction Market (2022 – 2030)
Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market – https://www.absolutemarketsinsights.com/reports/Global-Castration-Resistant-Prostate-Cancer-CRPC-Treatment-Market-2022-%E2%80%93-2030-1264
Global Compounding Chemotherapy Market – https://www.absolutemarketsinsights.com/reports/Global-Compounding-Chemotherapy-Market-2022-2030-1094
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: firstname.lastname@example.org
Phone: IN +91-7400-24-24-24, US +1-510-420-1213